ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!

Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case.

They would like ROS1+ patients who have taking crizotinib to share the following information (no names):

  • Demographic data (e.g., age, gender, date of diagnosis)
  • If currently or previously on crizotinib and for how long
  • Responses to crizotinib (e.g., reduction in size of tumor, no response, cancer progression)
  • Duration of the response
  • Side effects (what type, have they resolved, if yes, how)

Please email your responses immediately to Iwo Effiong at iwo@LungCancerCanada.ca.

Thank you for helping more ROS1 patients obtain access to crizotinib!

2 thoughts on “ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!

Comments are closed.